A First in Human Study, Evaluating the Safety and Efficacy of ADAM™ 1.0

NAActive, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

March 20, 2024

Study Completion Date

February 20, 2026

Conditions
Male ContraceptionHealthy Male Adults
Interventions
DEVICE

ADAM System

The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.

Trial Locations (3)

2500

South Coast Urology, Wollongong

3002

Epworth HealthCare, East Melbourne

4001

AndroUrology, Brisbane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Contraline, Inc

INDUSTRY